Objectives:

1. The learner will understand the pathophysiological rationale for complement inhibitor therapy for myasthenia gravis
2. The learner will be able to determine appropriate application of complement inhibitor therapy for myasthenia gravis patients; and
3. The learner will become familiar with the next generation of complement inhibitors under development.

Session date: 
05/16/2019 - 7:30am to 8:30am CDT
Location: 
UCMC
Chicago, IL 60637
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Henry Kaminski MD